Compare AAOI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | ZLAB |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2013 | 2017 |
| Metric | AAOI | ZLAB |
|---|---|---|
| Price | $180.79 | $19.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $66.80 | $49.60 |
| AVG Volume (30 Days) | ★ 8.8M | 626.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.78 | 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $119.87 | $9.75 |
| Revenue Next Year | $129.84 | $26.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $15.06 | $15.96 |
| 52 Week High | $191.87 | $44.34 |
| Indicator | AAOI | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.02 | 42.28 |
| Support Level | $28.35 | $19.51 |
| Resistance Level | $182.64 | $19.64 |
| Average True Range (ATR) | 21.46 | 0.99 |
| MACD | -1.12 | -0.47 |
| Stochastic Oscillator | 81.30 | 22.01 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.